Moleculin Biotech announced the enrollment and treatment of patients in an Investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of adults with glioblastoma. The study is being conducted under Northwestern University’s Investigative New Drug application, IND, which cross references the Company’s own IND, which received clearance from the U.S. Food and Drug Administration, FDA, in April 2022. This trial is funded by the National Institutes of Health and BrainUp, a non-profit organization dedicated to bringing awareness to brain cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin Biotech Raises Capital with Public Offering
- Moleculin Biotech Secures Funding for Drug Development Programs
- Moleculin Biotech prices $16.5M public offering
- Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Moleculin Biotech reports Q2 EPS ($1.70) vs. ($3.02) last year